Federal Report Tracks $15 Billion in State Cannabis Tax Revenue

Federal Data Aggregation Fills Reporting Gap

The report consolidates state-level cannabis tax data that's historically been scattered across dozens of individual state revenue departments, creating a single federal reference for market size and fiscal performance. The $15 billion figure spans fiscal years 2021 through 2025. It includes excise taxes, sales taxes, and cultivation taxes levied on legal cannabis transactions. Local taxes and fees collected by counties and municipalities aren't counted.

Investors and analysts have long complained about the difficulty of comparing state markets due to inconsistent reporting cadences, varying tax structures, and incomplete public disclosures. The aggregation effort addresses that gap. California alone accounted for approximately $4.2 billion of the five-year total, while Illinois contributed $1.8 billion and Colorado $1.6 billion, according to the federal compilation.

Revenue Growth Slowed in 2024 and 2025

Year-over-year revenue growth decelerated sharply in 2024 and 2025, with aggregate collections rising just 6% in 2024 and 4% in 2025 compared to double-digit growth rates in prior years. The slowdown reflects market saturation in mature states, price compression from oversupply, and ongoing competitive pressure from illicit operators who don't remit taxes.

Three factors drive the deceleration, according to the report: maturing demand curves in early-adopter states like Colorado and Washington, high statutory tax rates that push consumers toward untaxed channels, and the lack of federal banking access that keeps transaction costs elevated. States with excise tax rates above 20% experienced slower revenue growth than those with rates below 15%.

California's Underperformance Weighs on Aggregate Totals

California's cannabis tax revenue declined 8% in 2025 compared to 2024, the first year-over-year drop since the state launched adult-use sales in 2018. The decline erased roughly $340 million in expected collections and dragged down national growth rates. California's tax structure—a 15% excise tax plus local taxes that can reach 10%—has been cited by operators as a primary driver of illicit market persistence.

The state's revenue miss has direct implications for MSOs with heavy California exposure. Curaleaf, Cresco Labs, and Green Thumb Industries each derive between 18% and 24% of total revenue from California operations, according to their most recent 10-Q filings. Sustained revenue declines increase the risk of regulatory changes, including potential tax cuts that would pressure operator margins if passed through to consumers.

Illinois and New Jersey Lead Recent Growth

Illinois and New Jersey posted the highest revenue growth rates in 2025, with collections rising 22% and 34% respectively as both states added retail licenses and expanded geographic coverage. Illinois collected $531 million in cannabis tax revenue in 2025, up from $435 million in 2024. New Jersey's collections reached $287 million in its third full year of adult-use sales.

Growth in these states reflects the typical revenue trajectory of newly launched adult-use markets, where initial supply constraints give way to rapid retail expansion in years two through four. New Jersey's 34% growth rate aligns with patterns observed in Illinois, Michigan, and Massachusetts during comparable stages of market development. How long do these growth rates persist before hitting the saturation and price-compression dynamics now visible in California and Colorado? That's the question for investors.

Report Highlights Interstate Tax Structure Variation

The federal report documents wide variation in state tax structures, with effective tax rates ranging from 8% in some medical-only states to over 30% in jurisdictions with stacked excise, sales, and local taxes. States with simpler tax structures and lower rates generally collect more total revenue due to higher compliance and lower illicit-market substitution, the data shows.

Washington's single-point 37% excise tax generated $559 million in 2025 despite a smaller population than several lower-tax states. California's multi-layered tax system—cultivation taxes, distributor excise taxes, and retailer sales taxes—collected less per capita than Washington despite having a population nearly six times larger. The report doesn't make policy recommendations but provides state-level comparisons that are likely to inform upcoming tax reform debates in high-tax jurisdictions.

Investor Implications for MSO Valuation

The $15 billion five-year total implies an average annual state tax take of $3 billion, a figure that translates to roughly $12 billion to $15 billion in annual retail sales across legal markets when effective tax rates are reverse-engineered. That estimate aligns with industry surveys. It remains well below the $50 billion to $60 billion total addressable market figures cited by equity analysts when including illicit sales.

For public MSOs, the revenue data supports a bear-case view that legal market penetration is advancing more slowly than bulls anticipated. If state tax collections are growing at only 4% to 6% annually, and if MSOs are gaining share within the legal market, then consolidated revenue growth for the sector is likely to remain in the high single digits absent federal rescheduling or new state launches. That growth profile doesn't justify the 3x to 5x forward revenue multiples still assigned to some MSO equities.

Federal Data May Inform Rescheduling Debate

The report arrives as the DEA's rescheduling review enters its final phase, with the agency expected to issue a final rule on marijuana's Schedule III classification by the end of 2026. Proponents of rescheduling have argued that state cannabis markets represent a significant and stable source of tax revenue that federal policy should recognize rather than obstruct.

The $15 billion figure, while substantial, remains a small fraction of total federal tax receipts. It's unlikely to shift the political calculus around rescheduling on fiscal grounds alone. But the data does provide a concrete rebuttal to claims that state markets are negligible or transitory. For full background on this story, see the CannIntel topic hub on state cannabis tax revenue. The next major data point will be the DEA's final rule, expected no later than December 2026, and any accompanying economic analysis that references state market performance.

This is the first in what federal officials have indicated will be an annual series, with future editions expected to include more granular breakdowns by product category and tax type. Investors should track whether subsequent reports show stabilization or further deceleration in state revenue growth—that trend will directly inform MSO earnings forecasts and sector valuation multiples heading into 2027.